RAPP
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Rapport Therapeutics, Inc. Common Stock
- Nom
- Rapport Therapeutics, Inc. Common Stock
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.3B
- Employés
- 84
- PDG
- Abraham N. Ceesay
- Site web
- https://www.rapportrx.com
- Marché
- ACADANROAXSMCGTXCTNMLBRX
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 7 389 titres (~198 469,35 $ US) VENTE TOTALE: 8 942 titres (~294 026,16 $ US)
- Insiders
- Ceesay AbrahamSanchez RamiroYoung Wendy B.
- Total bought
-
$198,469
Avg buy (VWAP, 90d window) $26.54 vs last close $25.33 (-4.5%)
- Total sold
-
$3,444,998
Avg sell (VWAP, 90d window) $47.34 vs last close $25.33 (-46.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,380,551 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-23
- Liquidity
- Liquid $23,925,810/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-23 | Sanchez Ramiro | Buy · P | 3,600 | $27.35 | $98,478 | Form 4 |
| 2026-10-22 | Young Wendy B. | Buy · P | 3,789 | $26.39 | $99,992 | Form 4 |
| 2026-10-21 | Ceesay Abraham | Sell · S | 2,210 | $29.16 | $64,448 | Form 4 |
| 2026-10-21 | Ignelzi Troy A. | Buy · P | 5,500 | $26.10 | $143,550 | Form 4 |
| 2026-10-07 | Ceesay Abraham | Sell · S · 10b5-1 | 1,147 | $30.66 | $35,167 | Form 4 |
| 2026-10-06 | Ceesay Abraham | Sell · S · 10b5-1 | 3,375 | $32.03 | $108,106 | Form 4 |
| 2026-09-30 | Gault Cheryl | Sell · S · 10b5-1 | 2,075 | $33.76 | $70,043 | Form 4 |
| 2026-09-23 | Ceesay Abraham | Sell · S · 10b5-1 | 43 | $41.05 | $1,765 | Form 4 |
| 2026-09-08 | Ceesay Abraham | Sell · S · 10b5-1 | 1,069 | $46.01 | $49,190 | Form 4 |
| 2026-08-25 | Ceesay Abraham | Sell · S · 10b5-1 | 18,921 | $49.57 | $937,957 | Form 4 |
| 2026-08-25 | Yeleswaram Krishnaswamy | Sell · S · 10b5-1 | 16,201 | $51.06 | $827,184 | Form 4 |
| 2026-08-24 | Yeleswaram Krishnaswamy | Sell · S · 10b5-1 | 13,160 | $50.00 | $657,978 | Form 4 |
| 2026-08-19 | Yeleswaram Krishnaswamy | Sell · S · 10b5-1 | 404 | $49.90 | $20,160 | Form 4 |
| 2026-08-11 | Ceesay Abraham | Sell · S · 10b5-1 | 5,794 | $48.62 | $281,721 | Form 4 |
| 2026-08-10 | Ceesay Abraham | Sell · S · 10b5-1 | 8,370 | $46.75 | $391,280 | Form 4 |
| 2026-07-27 | Ceesay Abraham | Sell · S · 10b5-1 | 7 | $42.73 | $299 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
RAPP presents a classic pre-revenue biotech profile: a strong liquidity score (85) provides runway, but severely distressed fundamentals (score 15) with zero revenue and persistent cash burn cap the conviction.
The first sentence of the analysis written for RAPP on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 26.17 · operating margin 0.0%
Suggested stop 21.93, 1.5 ATR under the last close(13.4% under the last close). Reward/risk to the next stored resistance is 0.73. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $29.16, for a total transaction of $64,443.60. Following the sale, the chief executive officer owned 450,035 shares in the company, valued
- 2026-10-25 Rapport Therapeutics'' RAP-219 Hits Phase II Goals in Bipolar Mania Trial Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into Phase III development.
- 2026-10-20 Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
- 2026-10-20 Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data.
- 2026-10-20 Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging Positive trial data for Rapport''s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
- 2026-10-20 Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024)
- 2026-09-24 Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, supporting optimism for Phase 3 success. Analysts remain focused on the FOS opportunity, viewing the upcoming bipolar mania readout as potentially more instructive for safety than efficacy.
- 2026-09-22 Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
- 2026-09-22 4 Biotech Stocks With Key Clinical Readouts Expected This Fall KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
- 2026-09-16 Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 26.173 | 35.337 | 17.139 | 18.802 | |
| Quick Ratio | 26.173 | 35.337 | 17.139 | 18.802 | |
| Solvency Ratio | -3.977 | -8.149 | -0.192 | -0.879 | |
| Cash Ratio | 2.764 | 6.479 | 7.971 | 18.737 | |
| Price To Earnings Ratio | -10.608 | -4.693 | -21.895 | -71.724 | |
| Price To Earnings Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Price To Earnings Diluted Ratio | -10.608 | -4.693 | -21.895 | -71.724 | |
| Price To Earnings Diluted Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Price To Book Ratio | 2.941 | 1.205 | -14.670 | 21.453 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -16.180 | -5.472 | -13.049 | -118.671 | |
| Price To Operating Cash Flow Ratio | -16.294 | -5.675 | -13.835 | -129.067 | |
| Debt To Assets Ratio | 0.022 | 0.005 | 0.014 | 0.330 | |
| Debt To Equity Ratio | 0.024 | 0.005 | -0.084 | 0.535 | |
| Debt To Capital Ratio | 0.023 | 0.005 | -0.091 | 0.349 | |
| Long Term Debt To Capital Ratio | 0.018 | 0.000 | 0.000 | 0.349 | |
| Financial Leverage Ratio | 1.057 | 1.031 | -6.063 | 1.620 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.592 | -7.395 | -3.088 | -1.949 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 1.037 | 1.060 | 1.088 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -36.323 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -36.375 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.617 | -43.921 | -12.666 | -0.311 | |
| Capital Expenditure Coverage Ratio | -142.002 | -26.956 | -16.614 | -11.415 | |
| Dividend Paid And Capex Coverage Ratio | -142.002 | -26.956 | -16.614 | -11.415 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.155 | -3.802 | -8.540 | -38.419 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 26.173 | ▼-9.165 | ▲1.810 |
| Quick Ratio | 26.173 | ▼-9.165 | ▲1.810 |
| Solvency Ratio | -3.977 | ▲4.173 | ▼-0.677 |
| Cash Ratio | 2.764 | ▼-3.716 | ▼-6.224 |
| Price To Earnings Ratio | -10.608 | ▼-5.915 | ▲16.622 |
| Price To Earnings Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Forward Price To Earnings Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Price To Earnings Diluted Ratio | -10.608 | ▼-5.915 | ▲16.622 |
| Price To Earnings Diluted Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Price To Book Ratio | 2.941 | ▲1.736 | ▲0.209 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -16.180 | ▼-10.709 | ▲22.163 |
| Price To Operating Cash Flow Ratio | -16.294 | ▼-10.619 | ▲24.923 |
| Debt To Assets Ratio | 0.022 | ▲0.018 | ▼-0.070 |
| Debt To Equity Ratio | 0.024 | ▲0.019 | ▼-0.096 |
| Debt To Capital Ratio | 0.023 | ▲0.018 | ▼-0.048 |
| Long Term Debt To Capital Ratio | 0.018 | ▲0.018 | ▼-0.074 |
| Financial Leverage Ratio | 1.057 | ▲0.026 | ▲1.646 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.592 | ▲2.803 | ▼-0.336 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▼-0.030 | ▼-0.041 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲9.081 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲9.094 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -7.617 | ▲36.304 | ▲8.512 |
| Capital Expenditure Coverage Ratio | -142.002 | ▼-115.046 | ▼-92.755 |
| Dividend Paid And Capex Coverage Ratio | -142.002 | ▼-115.046 | ▼-92.755 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.155 | ▼-7.353 | ▲4.324 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.43B | $367.9M | $376.0M | $418.4M | |
| Enterprise value | $1.38B | $312.6M | $308.0M | $397.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.82x | -4.82x | -11.33x | -122.67x | |
| EV / Free cash flow | -15.71x | -4.65x | -10.69x | -112.79x | |
| EV / EBITDA | -11.15x | -3.80x | -8.54x | -38.42x | |
| Net debt / EBITDA | 0.33x | 0.67x | 1.89x | 2.00x | |
| Current ratio | 26.17x | 35.34x | 17.14x | 18.80x | |
| Income quality | 0.79x | 0.83x | 0.78x | 0.30x | |
| Graham net-net | $10 | $14 | -$2 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 89.1% | 94.3% | 96.1% | 102.7% | |
| Working capital | $479.5M | $301.0M | $142.1M | $29.6M | |
| Invested capital | $492.4M | $306.0M | $146.1M | $29.9M | |
| Return on assets | -21.8% | -24.9% | -22.4% | -33.7% | |
| Operating ROA | -30.2% | -35.3% | -38.7% | 0.0% | |
| Return on tangible assets | -21.8% | -24.9% | -22.4% | -33.7% | |
| Return on equity | -23.0% | -25.6% | 135.7% | -54.6% | |
| Return on invested capital | -25.2% | -27.1% | -24.6% | -34.6% | |
| Return on capital employed | -25.4% | -27.1% | -24.7% | -34.6% | |
| Earnings yield | -7.8% | -21.3% | -9.3% | -2.5% | |
| Free cash flow yield | -6.2% | -18.3% | -7.7% | -0.8% | |
| Capex / Op. cash flow | -0.7% | -3.7% | -6.0% | -8.8% | |
| Capex / Depreciation | 60.6% | 286.7% | 1460.7% | 1893.3% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 35283d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | -35283d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years